Technical Analysis for EQ - Equillium, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 20 DMA | Bearish | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -4.49% | |
Crossed Above 20 DMA | Bullish | -4.49% | |
NR7 | Range Contraction | -4.49% | |
Narrow Range Bar | Range Contraction | -4.49% | |
Inside Day | Range Contraction | -4.49% | |
Up 3 Days in a Row | Strength | -4.49% | |
Up 4 Days in a Row | Strength | -4.49% | |
20 DMA Resistance | Bearish | -1.16% |
Alert | Time |
---|---|
Fell Below 20 DMA | about 19 hours ago |
20 DMA Support | about 19 hours ago |
Outside Day | about 19 hours ago |
Down 5% | about 19 hours ago |
Down 3% | about 19 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium’s initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monocolonal antibody that selectively targets the novel immune checkpoint receptor CD6 and is designed to modulate T cells that drive immuno-inflammation. Itolizumab is a clinically-validated therapeutic with a favorable safety and tolerability profile. Equillium plans to advance EQ001 into clinical development in multiple indications of high unmet medical need and believes EQ001 has the potential to be a best-in-class disease modifying therapeutic.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Immunology Immune System Clinical Development Inflammation Monoclonal Antibody Antibody Autoimmunity Glycoproteins Immune Checkpoint Inflammatory Disorders
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Immunology Immune System Clinical Development Inflammation Monoclonal Antibody Antibody Autoimmunity Glycoproteins Immune Checkpoint Inflammatory Disorders
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.25 |
52 Week Low | 0.45 |
Average Volume | 180,544 |
200-Day Moving Average | 1.16 |
50-Day Moving Average | 2.12 |
20-Day Moving Average | 1.71 |
10-Day Moving Average | 1.65 |
Average True Range | 0.20 |
RSI (14) | 45.36 |
ADX | 27.1 |
+DI | 16.99 |
-DI | 24.19 |
Chandelier Exit (Long, 3 ATRs) | 1.48 |
Chandelier Exit (Short, 3 ATRs) | 1.93 |
Upper Bollinger Bands | 1.95 |
Lower Bollinger Band | 1.47 |
Percent B (%b) | 0.47 |
BandWidth | 27.83 |
MACD Line | -0.11 |
MACD Signal Line | -0.14 |
MACD Histogram | 0.0259 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.95 | ||||
Resistance 3 (R3) | 1.97 | 1.90 | 1.91 | ||
Resistance 2 (R2) | 1.90 | 1.84 | 1.89 | 1.90 | |
Resistance 1 (R1) | 1.80 | 1.79 | 1.77 | 1.78 | 1.88 |
Pivot Point | 1.73 | 1.73 | 1.71 | 1.72 | 1.73 |
Support 1 (S1) | 1.63 | 1.67 | 1.60 | 1.62 | 1.52 |
Support 2 (S2) | 1.56 | 1.63 | 1.55 | 1.50 | |
Support 3 (S3) | 1.46 | 1.56 | 1.49 | ||
Support 4 (S4) | 1.45 |